NMR measurements of NMR biomarker GlycA
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
Life of this patent
Estimating the term…
Abstract
Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
Claims12
A method of measuring GlycA, an NMR biomarker derived from a measure of composite NMR signal from carbohydrate portions of acute phase reactant glycoproteins containing N-acetylglucosamine and/or N-acetylgalactosamine moieties, comprising:
- performing Nuclear Magnetic Resonance to obtain a composite NMR spectrum of a fitting region of a biosample of a subject, wherein the spectrum is acquired using a one-pulse sequence;
- deconvolving the composite NMR spectrum using a defined deconvolution model with high density lipoprotein (HDL) components, low density lipoprotein (LDL) components, VLDL (very low density lipoprotein)/chylomicron components, and a plurality of curve fit functions associated with at least a GlycA peak region from 1.845 ppm to 2.080 ppm;
- and
- generating a measure of GlycA using the curve fit functions.
A method of determining coronary heart disease (CHD) risk for a patient, comprising:
- performing Nuclear Magnetic Resonance on a biosample from a subject to obtain a proton NMR spectrum, wherein the spectrum is acquired using a one-pulse sequence;
- evaluating NMR signal in a defined peak region of the proton NMR spectrum associated with GlycA of the biosample to determine a level of GlycA, wherein GlycA is an NMR biomarker derived from a measure of composite NMR signal from carbohydrate portions of acute phase reactant glycoproteins containing N-acetylglucosamine and/or N-acetylgalactosamine moieties;
- and determining a patient's risk of CHD based, at least in part, on the level of GlycA, wherein the defined peak region is centered at 2.00 ppm and extends from 1.845 ppm to 2.080 ppm for a sample at 47+/−0.2° C. in an NMR spectrometer.
Dependencies are inferred from the claim text.